Buscar
Novartis AG
NVSAñadir a la lista de seguimiento
159.870USD
+5.730+3.72%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
305.05BCap. mercado
22.75P/E TTM
Más Datos de Novartis AG Compañía
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Información de Novartis AG
Símbolo de cotizaciónNVS
Nombre de la empresaNovartis AG
Fecha de salida a bolsaMay 07, 2001
Director ejecutivoNarasimhan (Vasant)
Número de empleados75883
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 07
DirecciónLichtstrasse 35
CiudadBASEL
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísSwitzerland
Código postal4056
Teléfono41613241111
Sitio Webhttps://www.novartis.com/
Símbolo de cotizaciónNVS
Fecha de salida a bolsaMay 07, 2001
Director ejecutivoNarasimhan (Vasant)
Ejecutivos de Novartis AG
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vasant (Vas) Narasimhan, M.D.
Dr. Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Member of the Executive Committee
Chief Executive Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
Mr. Patrice Bula
Mr. Patrice Bula
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
--
--
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vasant (Vas) Narasimhan, M.D.
Dr. Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Member of the Executive Committee
Chief Executive Officer, Member of the Executive Committee
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Novartis AG?
Los cinco principales accionistas de Novartis AG son: Mr. Harry Kirsch
¿Cuántas instituciones poseen acciones de Novartis AG (NVS)?
A fecha de 2026Q1, 2164 instituciones poseen acciones de Novartis AG, con un valor de mercado combinado de aproximadamente 143.01M, lo que representa el 7.49% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1630148.00.
¿Cuál es la mayor fuente de ganancias de Novartis AG?
El 2026Q1, el segmento empresarial Rest of portfolio generó la ganancia más alta para Novartis AG, ascendiendo a 10.02B y representando el 18.37% de la ganancia total.